KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Non Operating Income (2016 - 2022)

Historic Non Operating Income for Biogen (BIIB) over the last 14 years, with Q1 2022 value amounting to -$263.3 million.

  • Biogen's Non Operating Income rose 4805.68% to -$263.3 million in Q1 2022 from the same period last year, while for Mar 2022 it was -$851.9 million, marking a year-over-year decrease of 86747.75%. This contributed to the annual value of -$305.6 million for FY2025, which is 1105.94% up from last year.
  • According to the latest figures from Q1 2022, Biogen's Non Operating Income is -$263.3 million, which was up 4805.68% from -$182.1 million recorded in Q4 2021.
  • Biogen's 5-year Non Operating Income high stood at $683.5 million for Q4 2020, and its period low was -$506.9 million during Q1 2021.
  • Over the past 5 years, Biogen's median Non Operating Income value was -$41.0 million (recorded in 2018), while the average stood at -$45.1 million.
  • In the last 5 years, Biogen's Non Operating Income crashed by 47217.39% in 2019 and then soared by 148640.97% in 2020.
  • Over the past 5 years, Biogen's Non Operating Income (Quarter) stood at -$28.6 million in 2018, then crashed by 72.38% to -$49.3 million in 2019, then skyrocketed by 1486.41% to $683.5 million in 2020, then crashed by 126.64% to -$182.1 million in 2021, then plummeted by 44.59% to -$263.3 million in 2022.
  • Its Non Operating Income was -$263.3 million in Q1 2022, compared to -$182.1 million in Q4 2021 and -$502.9 million in Q3 2021.